Pfrunder Arabelle, Schiesser Monika, Gerber Simone, Haschke Manuel, Bitzer Johannes, Drewe Juergen
Department of Clinical Pharmacology and Toxicology, Women's Hospital, University Clinic Basel/Kantonsspital, Basel, Switzerland.
Br J Clin Pharmacol. 2003 Dec;56(6):683-90. doi: 10.1046/j.1365-2125.2003.02005.x.
Breakthrough bleeding or even unwanted pregnancies have been reported in women during concomitant therapy with oral contraceptives and St John's wort extract. The aim of the present study was to investigate the effects of St John's wort extract on oral contraceptive therapy with respect to ovarian activity, breakthrough bleeding episodes and the pharmacokinetics of ethinyloestradiol and 3-ketodesogestrel.
Eighteen healthy females were treated with a low-dose oral contraceptive (0.02 mg ethinyloestradiol, 0.150 mg desogestrel) alone (control cycle) or combined with 300 mg St John's wort extract given twice daily (cycle A) or three times daily (cycle B). Ovarian activity was assessed by measuring follicle maturation and serum oestradiol and progesterone concentrations. The number of breakthrough bleeding episodes and the pharmacokinetics of ethinyloestradiol and 3-ketodesogestrel were assessed under steady-state conditions.
During concomitant administration of low-dose oral contraceptive and St John's wort, there was no significant change in follicle maturation, serum oestradiol or progesterone concentrations when compared with oral contraceptive treatment alone. However, significantly more subjects reported intracyclic bleeding during cycles A (13/17 (77%), P < 0.015) and cycle B (15/17 (88%), P < 0.001) than with oral contraceptives alone (6/17 (35%)). The AUC(0,24 h) and Cmax of ethinyloestradiol remained unchanged during all study cycles, whereas the AUC(0,24 h) and Cmax of 3-ketodesogestrel decreased significantly from 31.2 ng ml-1 h to 17.7 ng x ml-1 h (43.9%; 95% confidence interval (CI) -49.3, -38.5, P = 0.001) and from 3.6 ng x ml -1 to 3.0 ng x ml -1(17.8%; CI -29.9, -5.7, P = 0.005), respectively, during cycle A and by 41.7% (CI -47.9, -35.6; P = 0.001) and by 22.8% (CI -31.2, -13.3; P < 0.001) during cycle B respectively, compared with the control cycle.
There was no evidence of ovulation during low-dose oral contraceptive and St John's wort extract combination therapy, but intracyclic bleeding episodes increased. Bleeding irregularities may adversely effect compliance to oral contraceptives and together with St John's wort-induced decreases in serum 3-ketodesogestrel concentrations, enhance the risk of unintended pregnancies.
有报道称女性在口服避孕药与圣约翰草提取物联合治疗期间出现突破性出血甚至意外怀孕。本研究的目的是调查圣约翰草提取物对口服避孕药治疗在卵巢活性、突破性出血发作以及乙炔雌二醇和3 - 酮去氧孕烯的药代动力学方面的影响。
18名健康女性接受低剂量口服避孕药(0.02mg乙炔雌二醇,0.150mg去氧孕烯)单独治疗(对照周期),或联合每日两次(周期A)或每日三次(周期B)给予300mg圣约翰草提取物。通过测量卵泡成熟度以及血清雌二醇和孕酮浓度来评估卵巢活性。在稳态条件下评估突破性出血发作次数以及乙炔雌二醇和3 - 酮去氧孕烯的药代动力学。
在低剂量口服避孕药与圣约翰草联合给药期间,与单独口服避孕药治疗相比,卵泡成熟度、血清雌二醇或孕酮浓度没有显著变化。然而,与单独口服避孕药(6/17(35%))相比,在周期A(13/17(77%),P < 0.015)和周期B(15/17(88%),P < 0.001)期间报告有周期内出血的受试者明显更多。在所有研究周期中,乙炔雌二醇的AUC(0,24 h)和Cmax保持不变,而3 - 酮去氧孕烯的AUC(0,24 h)和Cmax在周期A中分别从31.2 ng·ml⁻¹·h显著降至17.7 ng·ml⁻¹·h(43.9%;95%置信区间(CI)-49.3,-38.5,P = 0.001)和从3.6 ng·ml⁻¹降至3.0 ng·ml⁻¹(17.8%;CI -29.9,-5.7,P = 0.005),在周期B中分别下降41.7%(CI -47.9,-35.6;P = 0.001)和22.8%(CI -31.2,-13.3;P < 0.001),与对照周期相比。
在低剂量口服避孕药与圣约翰草提取物联合治疗期间没有排卵证据,但周期内出血发作增加。出血不规律可能对口服避孕药的依从性产生不利影响,并且与圣约翰草引起的血清3 - 酮去氧孕烯浓度降低一起,增加意外怀孕的风险。